



SECTION 708A NOTICE AND APPENDIX 2A

This notice is given by Aroa Biosurgery Limited (**Company**) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

- (a) it has today issued:
 - a. 149,647 fully paid ordinary shares as the result of the cashless (net settled) exercise of 296,850 unlisted options held by employees of the Company;
 - b. 118,125 fully paid ordinary shares at a NZ\$0.10 issue price per share as the result of the exercise of unlisted options held by employees of the Company; and,
 - c. 81,925 fully paid ordinary shares at an AU\$0.75 issue price per share as the result of the exercise of options held by an entity associated with a director of the Company.
- (b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) Section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Jim McLean, Independent Chair.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody', its products are developed from the Company's proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa's products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio. Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

Contacts

Investor

Simon Hinsley
Investor Relations
shinsley@aroabio.com
+ 61 401 809 653

Media

Australia
Matthew Wright
matt@nwrcommunications.com.au
+61 451 896 420

New Zealand

Piet De Jong
piet.dejong@baldwinboyle.com
+64 21 812 766